Updated expert opinion guidelines regarding the effects of immunosuppressive agents on patch testing - 19/05/25
Doi : 10.1016/j.jaad.2025.01.078
Mykayla Sandler, BA a, b, Brandon L. Adler, MD c, Amber R. Atwater, MD d, Donald V. Belsito, MD e, Nina C. Botto, MD f, Joel G. DeKoven, MD g, Vincent A. DeLeo, MD c, Cory A. Dunnick, MD h, Joseph F. Fowler, MD i, Marie-Claude Houle, MD j, Howard I. Maibach, MD f, Christen M. Mowad, MD k, Margo J. Reeder, MD l, James S. Taylor, MD m, Erin M. Warshaw, MD, MS n, o, p, Peggy A. Wu, MD q, Jonathan H. Zippin, MD, PhD r, JiaDe Yu, MD, MS b, ⁎ 
a Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
c Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, Carolina
d Department of Dermatology, Duke University Medical Center, Durham, North Carolina
e Department of Dermatology, Columbia University Irving Medical School, New York, New York
f Department of Dermatology, University of California San Francisco, San Francisco, California
g Division of Dermatology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
h Department of Dermatology, Rocky Mountain Regional VAMC, Aurora, Colorado
i Division of Dermatology, University of Louisville, Louisville, Kentucky
j Division of Dermatology, Centre Hospitalier Universitaire de Québec, Laval University, Québec, Canada
k Department of Dermatology, Geisinger Medical Center, Danville, Pennsylvania
l Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
m Department of Dermatology, Cleveland Clinic, Cleveland, Ohio
n Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota
o Department of Dermatology, University of Minnesota Medical School, Minneapolis, Minnesota
p Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota
q Department of Dermatology, University of California Davis School of Medicine, Sacramento, California
r Department of Dermatology, Weill Cornell Medical College, New York, New York
∗Correspondence to: JiaDe Yu, MD, MS, Department of Dermatology, Massachusetts General Hospital, 50 Staniford St, Suite 200, Boston, MA 02114Department of DermatologyMassachusetts General Hospital50 Staniford StSuite 200BostonMA02114
Key words : allergic contact dermatitis, biologics, immunosuppression, patch testing
| Funding sources: None. |
|
| Previous presentation: This work has not been presented previously. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Reviewed and approved by the IRB for the NACDG under protocol 2021P001877. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 92 - N° 6
P. 1383-1385 - juin 2025 Retour au numéro
Article précédent
- Malignancy risk differs between hidradenitis suppurativa and pilonidal sinus disease
- Tara Sholji, Raaisa Islam, James Pham, Cindy Kok, John W. Frew
- Atopic dermatitis: Association of maternal and child history of celiac disease and the child’s development of atopic dermatitis
- Akash Rau, Gabrielle Leahr, Domenica Del Pozo, Ole Hoffstad, Zelma C. Chiesa Fuxench, Elizabeth Grice, David J. Margolis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?